Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
27,196,692
Number of holders
76
Total 13F shares, excl. options
20,915,564
Shares change
+2,802,083
Total reported value, excl. options
$111,896,376
Value change
+$14,469,349
Put/Call ratio
1.71%
Number of buys
40
Number of sells
-11
Price
$5.35

Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q1 2024

82 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q1 2024.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20,915,564 shares of 27,196,692 outstanding shares and own 76.9% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2,749,808 shares), Artal Group S.A. (2,505,013 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,071,914 shares), Samsara BioCapital, LLC (1,786,427 shares), Avidity Partners Management LP (1,673,538 shares), Point72 Asset Management, L.P. (1,471,771 shares), Flagship Pioneering Inc. (1,293,849 shares), VANGUARD GROUP INC (928,046 shares), Deep Track Capital, LP (828,485 shares), and Opaleye Management Inc. (787,545 shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.